| ΑD | 1 | | | |
|----|---|--|--|--|
| | | | | |

Award Number: W81XWH-11-1-0610

TITLE: Development of a Novel Microfluidic Platform for Multiple Sclerosis Study

PRINCIPAL INVESTIGATOR: In Hong Yang

CONTRACTING ORGANIZATION: Johns Hopkins University

Baltimore, MD, 21218

REPORT DATE: August 2012

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| F | REPORT DOC | | Form Approved OMB No. 0704-0188 | | | | | | |
|--|-------------------------------------|--|------------------------------------|---------------------------|--|--|--|--|--|
| data needed, and completing | and reviewing this collection of it | nformation. Send comments reg | arding this burden estimate or an | y other aspect of this co | hing existing data sources, gathering and maintaining the llection of information, including suggestions for reducing | | | | |
| 4302. Respondents should be | aware that notwithstanding any | other provision of law, no perso | n shall be subject to any penalty | | rson Davis Highway, Suite 1204, Arlington, VA 22202- a collection of information if it does not display a currently | | | | |
| 1. REPORT DATE | | R FORM TO THE ABOVE ADDI 2. REPORT TYPE | KE35. | 3. D | DATES COVERED | | | | |
| 01-08-2012 4. TITLE AND SUBTIT | | Final | | | Jul 2011 - 14 Jul 2012 CONTRACT NUMBER | | | | |
| | | dic Platform for Mu | ultiple Sclerosis St | | CONTRACT NUMBER | | | | |
| Bovolopmont of | a rever miorenaic | alo i lacionii loi ivic | anipio Colorodio Ct | , | GRANT NUMBER | | | | |
| | | W8 | 31XWH-11-1-0610 | | | | | | |
| | | | | 5c. | PROGRAM ELEMENT NUMBER | | | | |
| 6. AUTHOR(S) | | | | 5d. | PROJECT NUMBER | | | | |
| | | | | | | | | | |
| In Hong Yang | | 5e. ` | 5e. TASK NUMBER | | | | | | |
| | | | | 5f \ | 5f. WORK UNIT NUMBER | | | | |
| E-Mail: iyang3@jh | mi edu | | | 51. V | WORK UNIT NUMBER | | | | |
| 7. PERFORMING ORG | GANIZATION NAME(S) | AND ADDRESS(ES) | | 8. P | ERFORMING ORGANIZATION REPORT | | | | |
| Johns Hopkins | University, Ba | altimore, MD, 2 | 1205 | N | UMBER | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | IAME(S) AND ADDRES | S(ES) | 10. | SPONSOR/MONITOR'S ACRONYM(S) | | | | |
| - | I Research and Ma | teriel Command | | | | | | | |
| Fort Detrick, Mary | Ianu 21702-3012 | | | 11. | 11. SPONSOR/MONITOR'S REPORT | | | | |
| | | | | | NUMBER(S) | | | | |
| | | | | | | | | | |
| | VAILABILITY STATEN | | | | | | | | |
| Approved for Publ | ic Release; Distribu | ition Uniimitea | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| 13. SUPPLEMENTAR | Y NOTES | | | | | | | | |
| | | | | | | | | | |
| 14. ABSTRACT | | | | | | | | | |
| | s (NSC) are multi | potent cells isolate | ed from striatal tiss | sue and the s | ubventricular zone, which is one | | | | |
| | . , | | | | tion and differentiation occur | | | | |
| under physiological conditions and can be enhanced in certain pathological conditions following neural damage. | | | | | | | | | |
| | | | | | NSCs that affect the proliferation | | | | |
| | | | | | a novel NSC culture platform | | | | |
| that is capable o | t both compartme | entalizing and fluid | ically isolating mic | rodomains of | NSCs. | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| 15. SUBJECT TERMS | | | | | | | | | |
| | | | | | | | | | |
| | | | T .= | I | | | | | |
| 16. SECURITY CLASS | SIFICATION OF: | | 17. LIMITATION OF ABSTRACT | 18. NUMBER OF PAGES | 19a. NAME OF RESPONSIBLE PERSON USAMRMC | | | | |
| a. REPORT | b. ABSTRACT | c. THIS PAGE | | 3 | 19b. TELEPHONE NUMBER (include area | | | | |
| U | U | U | UU | 6 | code) | | | | |

Table of Contents

| | Page |
|------------------------------|------|
| Introduction | 4 |
| Body | 4 |
| Key Research Accomplishments | 4 |
| Reportable Outcomes | 4 |
| Conclusion | 5 |
| References | 6 |
| Appendices | 6 |

Introduction.

In certain autoimmune diseases of the central nervous system (CNS) in which regeneration does not occur, Neural Stem Cells (NSCs) fail to migrate to and proliferate at the site of damage. Migration and differentiation of NSCs have been studied *in vivo* as well as their response to factors released by activated T-cells. Recent progress in our understanding of the biology of NSCs has inspired interest in exploring the roles of neurogenesis capable NSC in the pathology and therapy of neurodegenerative disorders including multiple sclerosis (MS) [1-2]. Evidence suggests that NSC proliferation and differentiation occur under physiological conditions and can be enhanced in certain pathological conditions following neural damage [3-4]. This has largely been due to the inability to precisely control the fluidic microenvironment in standard *in vitro* preparations.

Body.

The goal of our proposal is the development of a novel microfluidic platform which can partially expose NSCs inflammatory T cell in a fluidically isolated manner. We have successfully developed a novel microfluidic compartmentalized NSC culture platform that enables culturing NSCs in multiple fluidic environments (Fig 1). NPCs migrated into and through the microchannel of the device and remained viable for 21 days, using visual inspection to determine if cells were alive. Microchannel length and well size in the lower layer were varied to determine any impact on cell survivability. Microchannels that were longer than 0.5 mm did not have high cell density due to lack of nutrients. The microchannels were limited to at least 0.5 mm due to physical difficulties fabricating smaller lengths. For well diameters less than 1.0 mm, NPCs entered the microchannel with higher probability (67%) than in the case of the 2 mm diameter (25%) by 14 days after seeding the neurosphere. Well size did not noticeably affect cell growth inside the microchannel. Fluidic isolation of fluorescent dye was achieved for 3 days using a flow of 10 microliters/hour for microchannels of cross sectional dimensions 50 microns x 50 microns. The method for examination was both visual examination by eye and examination under a fluorescence microscope.

Key research accomplishments

- \cdot Development of microfluidic platform for NSCs culture.
 - · Optimization of compartmentalized wells.
 - · Fluidic isolation of solution between compartmentalized wells.
 - · Successful culture of NSCs in the microfluidic device.

Reportable Outcomes

None.

Conclusion.

The device creates a system in which NPCs migrate through the microchannel within 20 days and with good survivability for multiple weeks. It also can fluidically isolate one compartment by introducing a steady but very low flow through the microchannel. The ability of the system to perform both tasks makes it suitable for a system to conduct the migration and differentiation experiments described earlier, as well as for studying cell-cell signaling in many applications.

Figure 1.




Figure 1 (A). Diagram of the device in use. A ball of NSCs is first placed in the well then allowed to settle and attach to the bottom of the well. After a period of a few days, NSCs have migrated through the microchannel to produce the desired model. (B). Picture from above the device. A main well with the NSCs has a microchannel to another well with the desired soluble factor. (C). Neurosphere (NPCs) were placed in the well in the lower PDMS layer next to the microchannel. (D). NPCs spread from neurosphere into the microchannel and continue to migrate/proliferate until NPCs reach the second well (Red Circle). (E). The fluidic isolation picture included here was not a cell culture, and a fluorescent dye was used merely to demonstrate the concept.

References.

- 1. Ikeda, R., et al., *Transplantation of neural cells derived from retinoic acid-treated cynomolgus monkey embryonic stem cells successfully improved motor function of hemiplegic mice with experimental brain injury*. Neurobiol Dis, 2005. **20**(1): p. 38-48.
- 2. Hayashi, J., et al., *Primate embryonic stem cell-derived neuronal progenitors transplanted into ischemic brain.* J Cereb Blood Flow Metab, 2006. **26**(7): p. 906-14.
- 3. Magavi, S.S., B.R. Leavitt, and J.D. Macklis, *Induction of neurogenesis in the neocortex of adult mice*. Nature, 2000. **405**(6789): p. 951-5.
- 4. Arvidsson, A., et al., *Neuronal replacement from endogenous precursors in the adult brain after stroke*. Nat Med, 2002. **8**(9): p. 963-70.

Appendices

None.